A cellular protein developed by scientists at the Institut Pasteur working in collaboration with the CNRS was found to be capable of acting as a restriction factor for hepatitis B virus by degrading the viral DNA.
Hepatitis B is a viral liver infection that can lead to acute or chronic conditions. Although there is a vaccine that offers protection against the virus, current treatments which prevent the virus from replicating are not curative for infected individuals.
HBV Screening
Tests used for screening hepatitis B are estimation of hepatitis B surface antigen (HBsAg), anti-HBc and anti-HBs antibodies.
Advertisement
‘Chronic infection with hepatitis B virus (HBV) affects more than 250 million people worldwide, putting them at high risk of developing serious liver conditions including liver cancer, an extremely severe form of cancer for which scientists have not yet found an effective treatment.’
Tweet it Now
Although several antiviral treatments can effectively inhibit HBV replication, they are not curative and do not fully eliminate the virus. It is therefore important to eliminate the virus in chronic carriers so as to prevent the disease from developing into cancer.
When viruses infect cells, they make use of cellular machinery, in other words the cell's built-in multiplication mechanisms. To combat viruses, some cellular proteins are capable of interfering with these mechanisms. These are known as viral restriction factors.
![Quiz on Hepatitis]( "Quiz on Hepatitis")
Hepatitis is a common liver disease that is responsible for mortality as well as morbidity. Test your knowledge on hepatitis by taking this quiz.
Scientists at the Institut Pasteur postulated that a protein mainly produced in several organs, including the liver, could take on the role of a restriction factor.
"During our research, we demonstrated that a cellular protein capable of degrading DNA could be incorporated into the viral particle and induce degradation of the hepatitis B virus genome," explains Jean-Pierre Vartanian from the Institut Pasteur's Molecular Retrovirology Unit. In this process, the enzyme, known as DNase I, produces empty virus particles.
DNase I, considered as a new antiviral restriction factor, is expressed in vitro in a hypoxic (oxygen-depleted) environment and also in patients infected with hepatitis B virus.
"The aim of our research is to use this protein to produce viral particles containing the nuclease so that we can pursue a "Trojan horse" approach," continues Jean-Pierre Vartanian. These particles will target infected liver cells, inducing degradation of the viral and cellular DNA found in them.
Source: Eurekalert
Quiz on Hepatitis
Hepatitis is a common liver disease that is responsible for mortality as well as morbidity. Test your knowledge on hepatitis by taking this quiz.
Advertisement
Scientists at the Institut Pasteur postulated that a protein mainly produced in several organs, including the liver, could take on the role of a restriction factor.
"During our research, we demonstrated that a cellular protein capable of degrading DNA could be incorporated into the viral particle and induce degradation of the hepatitis B virus genome," explains Jean-Pierre Vartanian from the Institut Pasteur's Molecular Retrovirology Unit. In this process, the enzyme, known as DNase I, produces empty virus particles.
DNase I, considered as a new antiviral restriction factor, is expressed in vitro in a hypoxic (oxygen-depleted) environment and also in patients infected with hepatitis B virus.
"The aim of our research is to use this protein to produce viral particles containing the nuclease so that we can pursue a "Trojan horse" approach," continues Jean-Pierre Vartanian. These particles will target infected liver cells, inducing degradation of the viral and cellular DNA found in them.
Source: Eurekalert
Hepatitis C Infected Organs can be Safely Transplanted: Study
Doctors can now safely transplant lungs or hearts from hepatitis C-positive donors without infecting the recipients.
Advertisement
 Hepatitis C Diagnosis Declines Slightly in EuropeNew study highlights a slight decline in hepatitis C diagnosis in Europe. However, the incidence of hepatitis C virus (HCV) infection was mostly higher in northern and western European countries than in southern European countries. | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
New study sheds light on the intrinsic, yet often overlooked, role of sleep preparation as a hardwired survival strategy.
Microgravity-induced bone loss in space, can be reduced by systemic delivery of NELL-1, a protein required for bone growth and its maintenance.
Researchers establish connections between Alzheimer's-linked genetic alterations and the functioning of brain cells.
Team at NeuroRestore introduces a groundbreaking gene therapy that has effectively promoted nerve regrowth and reconnection, post spinal cord injury.
Scientists aim to pinpoint particular functional pathways affected by these bacteria that may have an impact on skeletal health.
